Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 

November 2012

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study. Ogawa E, Furusyo N, Kajiwara E, et al. J Hepatol. 2012 Oct 22. pii: S0168-8278(12) 00816-1. doi: 10.1016/j.jhep.2012.10.017. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23099187

 

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis. Akuta N, Suzuki F, Seko Y, et al. Intervirology. 2012 Oct 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23037768

 

Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. Nagaoki Y, Aikata H, Kobayashi T, J Gastroenterol. 2012 Oct 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23053422

 

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. Akuta N, Suzuki F, Seko Y, et al. J Med Virol. 2012 Oct;84(10):1593-9. doi: 10.1002/jmv.23368.

http://www.ncbi.nlm.nih.gov/pubmed/22930507

 

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? Holmes JA, Desmond PV, Thompson AJ. J Viral Hepat. 2012 Oct;19(10):677-84. doi: 10.1111/jvh.12003.

http://www.ncbi.nlm.nih.gov/pubmed/22967098

 

Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. Martinez SM, Foucher J, Combis JM, et al. PLoS One. 2012;7(10):e47715. doi: 10.1371/journal.pone.0047715. Epub 2012 Oct 17.

http://www.ncbi.nlm.nih.gov/pubmed/23082200

 

Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis c virus immunity. Golden-Mason L, Stone AE, Bambha KM, Cheng L, Rosen HR. Hepatology. 2012 Oct;56(4):1214-22. doi: 10.1002/hep.25771.

http://www.ncbi.nlm.nih.gov/pubmed/22505144

 

Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy. Zhang L, Han F, Zhang D, Dou XG. Int J Mol Med. 2012 Oct 15. doi: 10.3892/ijmm.2012.1155. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23064792

 

Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease. White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB. J Clin Gastroenterol. 2012 Oct;46(9):779-88.

http://www.ncbi.nlm.nih.gov/pubmed/22955261

 

Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations. Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, Miller AH. Brain Behav Immun. 2012 Oct 13. pii: S0889-1591(12)00472-2. doi: 10.1016/j.bbi.2012.10.010. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23072726

 

Boceprevir With Peginterferon Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Flamm SL, Lawitz E, Jacobson I, et al. Clin Gastroenterol Hepatol. 2012 Oct 10. pii: S1542-3565(12)01160-3. doi: 10.1016/j.cgh.2012.10.006. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23064222

 

The role of serum cytokines in the pathogenesis of hepatic osteodystrophy in male cirrhotic patients. Soylu AR, Tuglu C, Arikan E, et al. Gastroenterol Res Pract. 2012;2012:425079. doi: 10.1155/2012/425079. Epub 2012 Oct 14.

http://www.ncbi.nlm.nih.gov/pubmed/23097664

 

Basic and Applied Science, Pre-Clinical Studies

 

Evaluation of IL-28B Polymorphisms and Serum IP-10 in Hepatitis C Infected Chimpanzees. Verstrepen BE, de Groot NG, Groothuismink ZM, et al. PLoS One. 2012;7 (10):e46645. doi: 10.1371/journal.pone.0046645. Epub 2012 Oct 30.

http://www.ncbi.nlm.nih.gov/pubmed/23118858

 

Single nucleotide polymorphisms in GALNT8 are associated with response to interferon therapy for chronic hepatitis C. Nakano R, Maekawa T, Abe H, et al. J Gen Virol. 2012 Oct 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23034592

 

25-hydroxyvitamin D(3) suppresses hepatitis C virus production. Matsumura T, Kato T, Sugiyama N, et al. Hepatology. 2012 Oct;56(4):1231-9. doi: 10.1002/hep.25763.

http://www.ncbi.nlm.nih.gov/pubmed/22487892

 

HIV/HCV Coinfection

 

Evaluation and treatment of hepatitis C in patients with human immunodeficiency virus.

Bakaj G, Valasiuk T, Prabhukhot R, Siraj D. South Med J. 2012 Oct;105(10):500-3. doi: 10.1097/SMJ.0b013e3182675d86.

http://www.ncbi.nlm.nih.gov/pubmed/23038477

 

Interleukin 28B rs12979860 (CT/TT) Genotype Is Associated with Milder Hepatic Damage in the Natural Evolution of HCV/HIV Coinfection. de la Fuente C, Hinojosa C, Gilabert I, et al. J Interferon Cytokine Res. 2012 Oct 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23030669

 

Low vitamin D levels are associated with impaired virologic response to PEGIFN+RBV therapy in HIV/HCV coinfected patients. Mandorfer M, Reiberger T, Payer BA, et al. AIDS. 2012 Oct 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23032421

 

Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals. Gillis J, Cooper C, Rourke S, et al. Qual Life Res. 2012 Oct 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23070749

 

Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Rivero-Juarez A, Mira JA, Camacho A, et al. Infection. 2012 Oct 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23065463

 

IL28B polymorphisms are associated with severity of liver disease in human immune-deficiency virus (HIV) patients coinfected with hepatitis C virus. Guzmán-Fulgencio M, Berenguer J, García-Álvarez M, et al. J Infect. 2012 Oct 25. pii: S0163-4453(12)00311-8. doi: 10.1016/j.jinf.2012.10.025. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23103287

 

Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection. Lo Re V 3rd, Volk J, Newcomb CW, et al. Hepatology. 2012 Nov;56(5):1688-98. doi: 10.1002/hep.25866. Epub 2012 Oct 14.

http://www.ncbi.nlm.nih.gov/pubmed/22619086

 

IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. Osinusi A, Chary A, Winters MA, et al. J Med Virol. 2012 Oct;84(10):1522-7. doi: 10.1002/jmv.23376.

http://www.ncbi.nlm.nih.gov/pubmed/22930497

 

Lack of a Clinically Significant Drug-Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir. de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Clin Infect Dis. 2012 Oct 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23001704

 

Complementary and Alternative Medicine

 

Anti-infective properties of Epigallocatechin-3-gallate (EGCG), a component of Green Tea.

Steinmann J, Buer J, Pietschmann T, Steinmann E. Br J Pharmacol. 2012 Oct 16. doi: 10.1111/bph.12009. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23072320

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Baseline Characteristics and Mortality Among People in Care for Chronic Viral Hepatitis: The Chronic Hepatitis Cohort Study. Moorman AC, Gordon SC, Rupp LB, et al. Clin Infect Dis. 2012 Oct 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22990852

 

Unhealthy Alcohol Use, HIV Infection and Risk of Liver Fibrosis in Drug Users with Hepatitis C. Muga R, Sanvisens A, Fuster D, et al. PLoS One. 2012;7(10):e46810. doi: 10.1371/journal.pone.0046810. Epub 2012 Oct 9.

http://www.ncbi.nlm.nih.gov/pubmed/23056462

 

Stochastic modeling of intra-household transmission of hepatitis C virus: evidence for substantial non-sexual infection. Akhtar S, Carpenter TE. J Infect. 2012 Oct 25. pii: S0163-4453(12)00306-4. doi: 10.1016/j.jinf.2012.10.020. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23103288

 

Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Gordon SC, Pockros PJ, Terrault NA, et al. Hepatology. 2012 Nov;56(5):1651-60. doi: 10.1002/hep.25842. Epub 2012 Oct 9.

http://www.ncbi.nlm.nih.gov/pubmed/22610658

 

Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. J Subst Abuse Treat. 2012 Dec;43(4):424-32. doi: 10.1016/j.jsat.2012.08.007. Epub 2012 Oct 2.

http://www.ncbi.nlm.nih.gov/pubmed/23036920

 

Knowledge, attitudes and barriers regarding vaccination against hepatitis A and B in patients with chronic hepatitis C virus infection: a survey of family medicine and internal medicine physicians in the United States. Tenner CT, Herzog K, Chaudhari S, Bini EJ, Weinshel EH. Int J Clin Pract. 2012 Oct;66(10):1009-13. doi: 10.1111/ijcp.12013.

http://www.ncbi.nlm.nih.gov/pubmed/22994334

 

The Impact of Ethnicity on Hepatitis C Virus Treatment Decisions and Outcomes. Lisker-Melman M, Walewski JL. Dig Dis Sci. 2012 Oct 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23065087

 

Comparison of hepatitis C virus treatment between incarcerated and community patients.

Rice JP, Burnett D, Tsotsis H, et al. Hepatology. 2012 Oct;56(4):1252-60. doi: 10.1002/ hep.25770.

http://www.ncbi.nlm.nih.gov/pubmed/22505121

 

Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence. Spradling PR, Rupp L, Moorman AC, et al. Clin Infect Dis. 2012 Oct;55(8):1047-1055. Epub 2012 Aug 8.

http://www.ncbi.nlm.nih.gov/pubmed/22875876

 

Liver Cancer

 

The role and clinical implications of microRNAs in hepatocellular carcinoma. Zhao X, Yang Z, Li G, et al. Sci China Life Sci. 2012 Oct;55(10):906-19. doi: 10.1007/s11427-012-4384-x. Epub 2012 Oct 31.

http://www.ncbi.nlm.nih.gov/pubmed/23108868

 

Promotion of hepatocellular carcinoma by hepatitis C virus. Bühler S, Bartenschlager R. Dig Dis. 2012;30(5):445-52. doi: 10.1159/000341688. Epub 2012 Oct 24.

http://www.ncbi.nlm.nih.gov/pubmed/23108300

 

Prognosis of Patients with Hepatocellular Carcinoma. Validation and Ranking of Established Staging-Systems in a Large Western HCC-Cohort. Op den Winkel M, Nagel D, Sappl J, et al. PLoS One. 2012;7(10):e45066. doi: 10.1371/journal.pone.0045066. Epub 2012 Oct 5.

http://www.ncbi.nlm.nih.gov/pubmed/23071507

 

Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. Wen CP, Lin J, Yang YC, et al. J Natl Cancer Inst. 2012 Oct 17;104(20):1599-611. doi: 10.1093/jnci/djs372.

http://www.ncbi.nlm.nih.gov/pubmed/23073549

 

Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study.

Oh JK, Shin HR, Lim MK, et al. BMC Cancer. 2012 Oct 5;12(1):452. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23039099

 

Association of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Gulnaz A, Sayyed AH, Amin F, et al. Eur J Gastroenterol Hepatol. 2012 Oct 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23044807

 

The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Cabrera R, Limaye AR, Horne P, et al. Aliment Pharmacol Ther. 2012 Oct 24. doi: 10.1111/apt.12098. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23094860